MetaCap

Pro-Dex (PDEX) vs Profound Medical (PROF)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pro-Dex (PDEX) has outperformed Profound Medical (PROF) over the past year, gaining 92.9% versus a gain of 6.2%. Over five years, PDEX leads with a +180.2% price change compared with -43.6% for PROF. Profound Medical is the larger company by market cap ($233.7 million vs $201.6 million), about 1.2 times the size.

Pro-Dex converts more of its revenue into profit, with a net margin of 17.6% versus -264.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PDEX+92.90%PROF+6.16%
+132%+54%-23%
Nov 21, 20251 yearNov 20, 2026
PDEX+208.22%PROF-47.62%
+276%+94%-88%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PDEX versus PROF key metrics
MetricPDEXPROF
Share price$63.00$6.38
Market cap$201.60M$233.68M
1-day change-0.77%-3.19%
YTD return+63.72%-18.93%
1-year return+92.90%+6.16%
5-year return+180.25%-43.64%
P/E ratio (TTM)17.36—
Forward P/E18.16—
EPS (TTM)$3.63$-0.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$77.55M$16.10M
Revenue growth (YoY)+16.45%+50.73%
Net income (latest FY)$13.66M$-42.57M
Gross margin31.38%70.77%
Operating margin16.75%-256.27%
Net margin17.62%-264.44%
52-week high$77.00$8.95
52-week low$32.14$4.80
Distance from 52-week high-18.18%-28.72%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+26.98%+74.61%
Average volume54.15K208.29K
Shares outstanding3.20M36.63M
Employees201162
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PDEX has outperformed PROF by 86.7 percentage points over the past year.
  • Pro-Dex is more profitable, keeping 17.6 cents of every revenue dollar as net income versus -264.4 cents for Profound Medical.
  • Profound Medical grew revenue faster in its latest fiscal year (+50.73% vs +16.45%).

About Pro-Dex

PDEX stock →

Pro-Dex, Inc. designs, develops, manufactures, and repairs powered surgical instruments for medical device original equipment manufacturers worldwide.

Health Care · Medical/Dental Instruments · 201 employees

About Profound Medical

PROF stock →

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.

Health Care · Medical/Dental Instruments · 162 employees

PDEX vs PROF FAQ

Which is bigger, Pro-Dex or Profound Medical?

Profound Medical (PROF) is larger, with a market capitalization of $233.68M compared with $201.60M for Pro-Dex (PDEX).

Which stock has performed better over the past year, PDEX or PROF?

PDEX returned +92.90% over the past 12 months, compared with +6.16% for PROF (price return, excluding dividends). Past performance does not predict future results.

Are Pro-Dex and Profound Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons